Cancer play Impact doubles in value after Hong Kong IPO: Public Equity Report

China-based oncology company Impact became the first biopharma to go public in Hong Kong since January, doubling in value and holding most of its aftermarket gains through the week’s end.

The HK$843.7 million ($107.8 million) offering by Impact Therapeutics Inc. (HKEX:7630) will support marketing and further development of PARP1/PARP2 inhibitor senaparib, approved in China as a first-line therapy for ovarian cancer. Impact’s clinical pipeline includes additional PARP inhibitors as well as synthetic lethal treatments targeting ATR and WEE1...